Nabriva Therapeutics plc saw its stock get a major boost on Monday morning after the company announced top-line results from their trial of a pneumonia drug.
Neovasc, Adaptimmune, Curis, Vericel and MannKind top the NASDAQ biotech stock list.
Moleculin Biotech announced it will meet with the European Medicines Agency (EMA) for the clinical trial authorization study of Annamycin treating acute myeloid leukemia.
Delcath Systems, MannKind, Zogenix, BioLife Solutions and BioDelivery Sciences top the NASDAQ biotech stock list.
Cogentix Medical, Molecular Templates, Celldex Therapeutics, Cerus and Kura Oncology top the NASDAQ biotech stock list.
Novavax, Agenus, Sierra Oncology, Durect and Cogentix top the NASDAQ biotech stock list.
Abeona Therapeutics is on the path to speed up its EB-101 gene therapy interventional study to a Phase 3 clinical trial.
VBI Vaccines announced a phase 3 clinical program for Sci-B-Vac after positive talks with the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Health Canada.
Actinium Pharmaceuticals received orphan drug designation for Actimab-A by the European Medicines Agency.
uniQure N.V. announced it won’t seek a marketing authorization renewal for Glybera in the European market, which is set to expire in October this year.